Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings Routine +

Alzai Health Corp. Completes Initial Public Offering

Early-stage AI diagnostics IPO raises $4M to fund Alzheimer's screening R&D and commercialization.

By The Northwire Desk — AI Analysis Jun 09, 2026 · 08:23 ALZI NaN
Executive Summary
  • Alzai Health Corp. successfully closed its initial public offering on June 9, 2026.
  • The company sold 10,125,000 units at $0.40 per unit, generating $4,050,000 in gross proceeds.
  • Each unit consists of one common share and one-half warrant exercisable at $0.60 per share until June 2028.
  • Warrants include an acceleration clause if the VWAP reaches $0.90 for 10 consecutive trading days.
  • Net proceeds are designated for research and development, sales and marketing, and general working capital.
  • Common shares resumed trading on the TSX Venture Exchange under the ticker ALZI following a brief halt.
Material Impact
  • This is a financing event that provides initial public market liquidity and seed capital.
  • The capital raise is modest ($4.05M gross), which is standard for early-stage ventures but insufficient for long-term commercialization without follow-on offerings.
  • Immediate dilution occurs via the 10.125M new shares issued, with additional potential dilution from warrants and agent warrants.
  • No operational, revenue, or product milestone impact is disclosed in this release; the company remains in the pre-revenue development phase.
ALZI · Price
Company Overview
  • Alzai Health Corp. develops an AI-driven, non-invasive Alzheimer’s disease risk screening solution.
  • The platform utilizes pre-existing clinical data to enable earlier diagnosis and intervention.
  • The company is in the early development stage, focusing on R&D and commercialization preparation.
Read the original news release →

More from NaN

Jun 05, 2026 · 16:15

AI-driven Alzheimer's screening startup prepares for TSXV debut

Financings Apr 22, 2026 · 16:17

Alzai Health Files Final Prospectus for $4M Best-Efforts IPO

Financings